From Venom to Medicine: How Snake and Spider Toxins Become Drugs | Research

The takeaway

Millions of years of venom evolution have produced highly selective peptide toxins that serve as powerful drug leads, with several already in clinical use.

Millions of years
Of evolutionary optimization have made venom peptides exceptionally potent and selective therapeutic leads

What the researchers found

Venom-derived peptide toxins possess optimized pharmaceutical properties — high selectivity, potency, protease resistance, and low immunogenicity — making them ideal drug leads with several already approved.

Why it matters

Venoms represent a vast, largely untapped library of bioactive peptides that evolution has already optimized for potency and selectivity, accelerating drug discovery.

The numbers in context

Multiple approved snake venom drugs; spider venom peptides in clinical development; complex disulfide scaffolds; targets include ion channels, receptors, coagulation proteins

How the study worked

Narrative review covering venom biochemistry, structural diversity, evolution of toxin scaffolds, and examples of approved and developmental venom-derived drugs.

Who was studied

N/A (literature review of venom-derived drug development)

What this study cannot tell us

Overview review without systematic methodology. Limited detail on specific clinical trial results.

How to read the evidence

Review article citing approved drugs and clinical trials but presenting no new data.

When this study was published

Published in 2020. Venom-derived drug development continues to advance with new candidates entering clinical trials.

The bigger picture

Venom-derived peptide drugs exemplify how nature's molecular arsenal can be harnessed for human medicine, with applications spanning cardiovascular disease, pain, and neurological conditions.

Questions still open

Which undiscovered venom peptides might yield the next breakthrough drug?
Can synthetic modifications improve venom peptide pharmacokinetics for oral delivery?
How can high-throughput venom screening accelerate drug discovery?

Common questions

How are venom toxins turned into medicines?

Scientists isolate specific peptide toxins from venom, identify their molecular targets, and modify them to reduce toxicity while preserving therapeutic activity. The resulting drugs are highly selective because evolution has refined them over millions of years.

What venom-derived drugs are already approved?

Several are in clinical use, including captopril (from pit viper venom, for high blood pressure), eptifibatide (from rattlesnake, for blood clots), and ziconotide (from cone snail, for severe pain). More are in clinical development.

Read the original research

Snake- and Spider-Venom-Derived Toxins as Lead Compounds for Drug Development.

Methods in molecular biology (Clifton, N.J.), 2068, 3-26

View on PubMed ↗Publisher’s paper ↗

Citation

Lazarovici, Philip. (2020). Snake- and Spider-Venom-Derived Toxins as Lead Compounds for Drug Development.. Methods in molecular biology (Clifton, N.J.), 2068, 3-26. https://doi.org/10.1007/978-1-4939-9845-6_1